ArticleFrontiers in medicine2020
Lytic Activity of Polyvalent Staphylococcal Bacteriophage PhiSA012 and Its Endolysin Lys-PhiSA012 Against Antibiotic-Resistant Staphylococcal Clinical Isolates From Canine Skin Infection Sites.
Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Bacteriophage and Fusidic Acid Have Synergistic Effect Against Meticillin-Resistant Staphylococcus pseudintermedius in Ex Vivo Canine Dermis Model.Veterinary dermatology · 2026Article
- Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance.Nature communications · 2025Review
- Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.Infectious diseases and therapy · 2025Review
- Antimicrobial Strategies Proposed for the Treatment ofVeterinary sciences · 2024Review
- Bacteriophage Therapy in Companion and Farm Animals.Antibiotics (Basel, Switzerland) · 2024Review
- Antibacterial and Anti-Biofilm Efficacy of Endolysin LysAB1245 against a Panel of Important Pathogens.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Harnessing a T1 Phage-Derived Spanin for Developing Phage-Based Antimicrobial Development.Biodesign research · 2024Article
- Topical Bacteriophage Therapy for Staphylococcal Superficial Pyoderma in Horses: A Double-Blind, Placebo-Controlled Pilot Study.Pathogens (Basel, Switzerland) · 2023Article
- Biological properties of Staphylococcus virus ΦSA012 for phage therapy.Scientific reports · 2022Article
- Rapid, Cheap, and Effective COVID-19 Diagnostics for Africa.Diagnostics (Basel, Switzerland) · 2021Review
- The Complex Diseases ofVeterinary sciences · 2021Review
- Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections.Frontiers in molecular biosciences · 2021Review
- Alternative Anti-Infective Treatments to Traditional Antibiotherapy against Staphylococcal Veterinary Pathogens.Antibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spread of antibiotic-resistant bacteria (ARB) in human and veterinary medicine is of global concern. Notably, the emergence of methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.